To achieve our corporate mission of ‘Heal the World for Better Life’, we will move on to Innovation No.1 inno.N to develop global innovative new drugs with a spirit of creation and innovation and to reward the people and customers for their support.
About Us
inno.N was established in 1984 as CJ CheilJedang Pharmaceutical Business Division, based on 30 years of pharmaceutical business know-how.
HEPACCINE-B
In 1986, we developed hepatitis prevention vaccine 'Hepaccin-B' with pure domestic technology. We were recognized for our technological capability by mass-producing ‘interferon,’ which was a state-of-the-art basic medicine at that time and 7-ACA, the raw material that requires fine chemical technology.
Bag-type IV Solutions
By producing safe-flex bags for the first time in Korea in 1992, we have brought innovation to the healthcare environment where glass containers used to cause inconvenience in use.
CONDITION
CONDITION, the most popular anti-hangover drink in Korea, has been the indisputable No. 1 brand since 1992 when it first opened the anti-hangover drink market in Korea.
EPOKINE
In 1995, inno.N was the first domestic pharmaceutical company to achieve $ 100 million in exports and led the growth of the industry. With the continuous R&D investment, we launched a renal anemia treatment EPO formulation (product name: EPOKINE) in 1998 and this was the world's third and for the first time in Korea, leading the localization of pharmaceuticals.
OSONG Plant
In 2006, we successfully strengthened our product portfolio by merge and acquisition of Han-il Pharmaceutical Corp. In 2010, we completed the construction of the Osong plant, the world-class pharmaceutical production facility, giving a leap to become a global pharmaceutical company.
To make the foundation for a 100-year company from CJ Healthcare to inno.N in 2020, we are creating real innovations in global high-tech pharmaceutical
On March 2019, inno.N launched K-CAB Tab.(ingredient name: tegoprazan), a new drug for Gastroesophageal acid reflux, in Korea. K-CAB Tab is not only resulted in the largest performance among new drugs in the first year of its launch, but also exported to 22 countries such as China, Thailand, Indonesia, and 17 nations in Central and South America.
inno.N enhances the speed and success of new drug development through open innovation with domestic and overseas biotech companies and universities, and concentrates its own ability on securing future innovative technologies.
In 2014, we made a business alliance to develop protein therapeutics with Pangen. In May 2016, we signed a joint development contract with Y-BioLogics, a new antibody developing company, for a dual target antibody, and we have been co-developing immune anticancer drugs, etc. Furthermore, we are leading the development of the Korean domestic pharmaceutical industry by adapting advanced technologies from venture companies in the US, Japan, and Europe into Korea.
“Innovate New & Next”
We will step forward as Great inno.N
The pharmaceutical industry is a technology-intensive core industry which will lead us in the era of the Fourth Industrial Revolution.
With the philosophy of providing patriotic service as a pharmaceutical company, we started our business in 1984 as a division of CheilJedang Pharmaceuticals. Based on our 30-year history in pharmaceutical business, we have separated from Head Company and became independent in 2014 to become a global pharmaceutical company. In April 2018, we separated from CJ Group(CJ CheilJedang Co., Ltd. ) and became a family with KOLMAR Korea. Then, in order to lead a new innovation in global pharmaceuticals in 2020, we changed the company name from CJ to inno.N and started a challenge to create a 100-year-old company.
The last 30 years of inno.N has been a journey of creation. The first launch of EPO formulation (product name: Epokine) and hepatitis vaccine in Korea, launch of infusion solution using Safe-flex bag, and the development of a hangover drink market through hangover drink ‘CONDITION’, etc. were the part of our creative journey and the journey is still underway.
Based on our successful experiences, we are creating brighter future by building global network with Open Innovation for domestics, overseas ventures and universities. Also, exporting technology of digestive new drugs to speed up the development of new drugs made new industrial ecosystems which all can coexist for a better future.
By persistent investments in R&D and ceaseless efforts for technological development, inno.N will expand in overseas bases such as China, Japan and Vietnam and grow continuously as a proud global pharmaceutical company.
By developing innovative global drugs which can contribute to 100 year health, we will reborn as Great inno.N which people can trust and realize our business vision of ‘Heal the World for Better Life.’
I would like to express my deep gratitude to our customers again for visiting our homepage.
On March 2019, inno.N launched K-CAB Tab.(ingredient name: tegoprazan), a new drug for Gastroesophageal acid reflux, in Korea. K-CAB Tab is not only resulted in the largest performance among new drugs in the first year of its launch, but also exported to 22 countries such as China, Thailand, Indonesia, and 17 nations in Central and South America.
inno.N enhances the speed and success of new drug development through open innovation with domestic and overseas biotech companies and universities, and concentrates its own ability on securing future innovative technologies.
In 2014, we made a business alliance to develop protein therapeutics with Pangen. In May 2016, we signed a joint development contract with Y-BioLogics, a new antibody developing company, for a dual target antibody, and we have been co-developing immune anticancer drugs, etc. Furthermore, we are leading the development of the Korean domestic pharmaceutical industry by adapting advanced technologies from venture companies in the US, Japan, and Europe into Korea.
